论文部分内容阅读
目的探讨绝经前后乳腺癌组织中雌激素的变化及其与乳腺癌组织TGF-β1和Bcl-2表达水平的相关性。方法选取2014年10月-2015年9月在就诊的该院乳腺癌患者行手术切除的患者74例为研究对象,分为绝经前组和绝经后组,每组各37例。采用ELISA试剂盒检测乳腺癌患者的血清、癌组织及癌旁正常组织的E2含量;采用免疫印迹法检测癌组织中的TGF-β1和Bcl-2的表达水平及免疫组织化法检测癌组织中的ER表达情况。结果绝经后组乳腺癌患者的外周血清中E2含量显著低于绝经前组(P<0.001),但癌组织E2的表达水平与绝经前组比较差异无统计学意义(P>0.05),且两组患者E2的表达水平均显著高于癌旁正常乳腺组织(P<0.001);经免疫组化检测证实,绝经前、绝经后两组各有18例和20例(54.1%)ER表达阳性患者,差异无统计学意义(P>0.05);但ER阳性乳腺癌患者的癌组织TGF-β1和Bcl-2表达水平均与E2含量呈正相关(P<0.05)。结论乳腺癌组织中的E2表达水平是决定肿瘤细胞TGF-β1和Bcl-2表达水平的关键因素,且不受绝经期的影响,尤其在ER阳性乳腺癌患者中的表现最为显著。
Objective To investigate the changes of estrogen in breast cancer tissues before and after menopause and its correlation with the expression of TGF-β1 and Bcl-2 in breast cancer tissues. Methods Totally 74 patients undergoing surgical resection from October 2014 to September 2015 in our hospital were divided into premenopausal group and postmenopausal group with 37 cases in each group. The contents of E2 in serum, cancer tissues and adjacent normal tissues of breast cancer patients were detected by ELISA kit. The expression of TGF-β1 and Bcl-2 in cancer tissues was detected by Western blotting and the expression of Bcl-2 ER expression. Results The level of E2 in the peripheral blood serum of postmenopausal breast cancer patients was significantly lower than that in the premenopausal group (P <0.001), but there was no significant difference in the expression of E2 between the premenopausal and postmenopausal women (P> 0.05) The expression of E2 was significantly higher in patients than in normal breast tissues (P <0.001). Immunohistochemical results showed that there were 18 and 20 (54.1%) ER positive patients in premenopausal and postmenopausal women (P> 0.05). However, the expression levels of TGF-β1 and Bcl-2 in cancerous tissues of ER-positive breast cancer patients were positively correlated with the levels of E2 (P <0.05). Conclusion The expression level of E2 in breast cancer tissue is the key factor that determines the expression of TGF-β1 and Bcl-2 in tumor cells, and is not affected by menopause, especially in patients with ER-positive breast cancer.